Background/Objectives: According to the modified Mason classification, radial head fractures can be treated with open reduction and internal fixation (ORIF), radial head arthroplasty, or resection. This study by the Department of Traumatology and Orthopedics of the Military Institute of Medicine aimed to compare the clinical and radiological outcomes of fractures treated with ORIF. Methods: This retrospective study analyzed 55 patients with radial head fractures treated between April 2020 and February 2023. Fractures were classified using Mason system as 15 type II, 26 type III, and 14 type IV. Clinical outcomes were evaluated using the VAS for pain, Broberg–Morrey scale, and the DASH questionnaire, alongside assessments of range of motion, grip strength, and elbow stability. Follow-up radiographs examined bone union, bone fragments displacement, degenerative changes and periarticular ossification. Results: The mean follow-up period was 21.0 ± 10.2 months. There were no statistically significant differences in VAS scale results for Mason types II, III, and IV fractures (4.0 vs. 6.0 vs. 5.0, respectively; p = 0.825), the Broberg–Morrey scale (82.0 ± 15.2 vs. 80.9 ± 15.5 vs. 84.2 ± 15.1, respectively; p = 0.845), or the DASH questionnaire (10.0 vs. 11.7 vs. 17.5, respectively; p = 0.937). Mean extension deficit and supination angles were at the limit of statistical significance (p = 0.076 and p = 0.051). No cases of lateral instability were observed, whereas medial instability was seen in only one case. Bone union was observed in 97.5% of cases, with elbow joint osteoarthritis and periarticular ossification in 15.0% and 45.0% of cases, respectively. Conclusions: Mason type II, III and IV radial head fractures treated with open reduction and internal fixation showed good functional and radiological outcomes with rare complications, including degenerative changes, periarticular ossifications and nonunion.

Background: Modern radiotherapy techniques have improved the safety of prostate cancer treatment, but acute gastrointestinal and genitourinary toxicity remains a common clinical problem. Early identification of patients who are likely to develop treatment-related adverse effects may help optimize supportive care. This study evaluated the relationships between clinical characteristics, radiotherapy planning parameters, systemic inflammatory biomarkers, and acute pelvic toxicity during hypofractionated radiotherapy. Materials and Methods: We retrospectively analyzed 142 patients with histologically confirmed prostate cancer who underwent external beam radiotherapy at the Provincial Integrated Hospital in Płock, Poland, between October 2024 and March 2026. Clinical, laboratory, and radiotherapy planning data were obtained from institutional electronic records. Laboratory analyses included CRP, creatinine, total leukocyte, neutrophil, lymphocyte, erythrocyte and platelet counts, hemoglobin, and hematocrit. Rectal and bladder toxicity was prospectively graded according to the RTOG/EORTC criteria at 2 and 4 weeks after treatment initiation. Correlation and multivariable regression analyses were performed to identify factors associated with acute treatment-related toxicity. Results: Radiotherapy significantly reduced leukocyte and lymphocyte counts (both p < 0.001) and produced smaller reductions in erythrocyte count, hemoglobin, hematocrit, and absolute neutrophil count (all p < 0.05). Patients who reported rectal or urinary symptoms early during treatment generally continued to experience toxicity later in the treatment course. Rectal and bladder toxicities were positively correlated, indicating that patients with toxicity affecting one pelvic organ frequently developed symptoms in the other. Routine inflammatory biomarkers and most dosimetric parameters showed limited independent value for predicting clinically relevant acute toxicity. Conclusions: Early gastrointestinal and genitourinary toxicity appears to be a useful clinical indicator of persistent treatment-related symptoms during hypofractionated prostate radiotherapy. Early rectal and bladder toxicity was associated with toxicity later during treatment, whereas routine laboratory markers and most dosimetric parameters showed limited independent associations with acute pelvic toxicity.

Background and Objectives: Flank bulging is a recognized consequence of open renal surgery through a lumbotomy, but its clinical relevance and relationship with postoperative sensory changes are not well defined. We assessed the frequency and clinical burden of postoperative flank bulging, its overlap with sensory disturbances, and procedure-related factors associated with its occurrence. Materials and Methods: We reviewed 407 patients who underwent open renal surgery through a subcostal lumbotomy between 2018 and 2023. Flank bulging was the primary outcome. We also recorded scar hypoesthesia, wider areas of sensory loss, and whether patients found the resulting deformity bothersome. Factors associated with bulging were explored using multivariable logistic regression, with a separate analysis comparing nephron-sparing surgery (NSS) and radical nephrectomy. Results: Flank bulging was found in 88 patients (21.6%). Scar hypoesthesia occurred in 14.0% and more extensive sensory loss in 7.1%. Sensory abnormalities showed a strongly nested clinical pattern: all patients with scar hypoesthesia had flank bulging, and all extended sensory deficits occurred among patients with both bulging and scar hypoesthesia. All patients with scar hypoesthesia also had bulging, while wider sensory loss was seen only when both were present. Among patients for whom this information was available, 52.9% described the bulging as bothersome. It was more common after NSS than after radical nephrectomy (27.0% vs. 16.3%). The difference persisted after adjustment for age and sex (aOR 2.05, 95% CI 1.17–3.59), corresponding to an adjusted absolute risk difference of 11.8 percentage points (95% CI 2.4–20.8). Conclusions: About one in five patients developed flank bulging after open renal surgery through a lumbotomy, and many of those affected found it bothersome. The accompanying sensory changes raise the possibility that nerve injury contributes to this complication, although our data cannot establish the underlying mechanism. The higher rate observed after NSS compared with radical nephrectomy also warrants further study. Prospective assessment with standardized imaging and more detailed operative data may help explain these findings and identify factors that could reduce the risk of postoperative bulging.

Background and Objectives: Benign prostatic hyperplasia (BPH) is one of the most common chronic conditions in older men, significantly affecting quality of life (QoL) by causing lower urinary tract symptoms (LUTS). 5-alpha-reductase inhibitors (5-ARIs) such as finasteride and dutasteride remain a cornerstone of pharmacotherapy for BPH; however, comparative real-world data are limited. The aim of the present study was to compare the therapeutic outcomes of finasteride and dutasteride in patients diagnosed with BPH. Materials and Methods: This retrospective clinical study analyzed patients with BPH treated by either finasteride or dutasteride. Clinical parameters, including the Interna-tional Prostate Symptom Score (IPSS), QoL index, and International Index of Erectile Function-5 (IIEF-5) score; urodynamic outcomes, including maximum urinary flow rate (Qmax), average flow rate (Qave), and post-void residual urine volume (PVR); and bi-ochemical markers, including prostate-specific antigen (PSA) and creatinine levels, were assessed at baseline and after at least 6 months of continuous therapy and underwent cross-sectional statistical analysis, with significance set at p < 0.05. Results: Both treatment groups demonstrated significant improvements in clinical and urodynamic outcomes. Compared with finasteride, dutasteride was associated with greater reductions in the prostate volume and PSA levels as well as a greater im-provement in “IPSS”. Erectile function (IIEF-5) was comparable. Renal function param-eters remained stable in both groups. Predictive analysis revealed that higher body mass index and older age correlated with worse IIEF-5 scores in the finasteride group, whereas the baseline prostate volume was the key differentiating factor in the dutasteride group. Conclusions: Both 5-ARIs effectively reduced the severity of LUTS and improved uro-dynamic parameters in patients with BPH. Dutasteride showed superiority in reducing the prostate volume and PSA levels, while the overall safety profiles of both drugs were comparable. These findings highlight the importance of individualized therapy tailored to patient-specific clinical characteristics.

Background and Objectives: Benign prostatic hyperplasia (BPH) is one of the most common chronic conditions in older men, significantly impairing quality of life (QoL) by causing lower urinary tract symptoms (LUTSs). 5-alpha-reductase inhibitors (5-ARIs), including finasteride and dutasteride, remain a cornerstone of pharmacotherapy for BPH; however, comparative real-world data remain limited. The aim of this retrospective clinical study was to compare the therapeutic efficacy and safety of finasteride and dutasteride in patients with BPH. Materials and Methods: A total of 401 patients with BPH were retrospectively analyzed: 162 received finasteride and 239 received dutasteride. Clinical parameters, including the International Prostate Symptom Score (IPSS), Quality of Life (QoL) index, and International Index of Erectile Function-5 (IIEF-5) score; urodynamic outcomes, including maximum urinary flow rate (Qmax), average flow rate (Qave), and post-void residual urine volume (PVR); and biochemical markers, including prostate-specific antigen (PSA) and serum creatinine levels, were evaluated at baseline and after at least 6 months of continuous therapy. Statistical significance was defined as p < 0.05. Results: Both treatment groups demonstrated significant within-group improvements in LUTS severity and urodynamic outcomes (p < 0.001 for IPSS, Qmax, and QoL). Compared with finasteride, dutasteride achieved greater reductions in prostate volume (−26.3% vs. −18.1%, p = 0.008) and PSA levels (−43.7% vs. −32.5%, p = 0.014), as well as a slightly greater improvement in IPSS (−6.8 ± 3.9 vs. −5.9 ± 3.6, p = 0.042). Both drugs showed comparable effects on erectile function, as indicated by similar IIEF-5 score changes (Δ = −0.9 ± 2.8 vs. −0.7 ± 2.5, p = 0.51), confirming that neither agent demonstrated a clinically meaningful difference in sexual outcomes. Renal function parameters remained stable in both cohorts. Multivariate analysis identified higher BMI and older age as independent predictors of lower IIEF-5 scores in the finasteride group, while baseline prostate volume was the principal determinant of response in the dutasteride group. Conclusions: Both 5-ARIs effectively reduced LUTS severity and improved urodynamic parameters in men with BPH. Dutasteride demonstrated superior reductions in prostate volume and PSA, while both agents had comparable effects on sexual and renal function. These findings provide real-world evidence supporting the individualization of 5-ARI therapy according to patient-specific clinical characteristics.

Background: Persistent sexual and psychological symptoms after finasteride discontinuation have been reported; however, factors associated with symptom severity remain insufficiently characterized. Methods: This cross-sectional study included 129 adult men with prior finasteride exposure for male pattern hair loss or benign prostatic hyperplasia. Sexual function, depressive symptoms, and anxiety were assessed using the International Index of Erectile Function (IIEF), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7), respectively. Associations between clinical variables (age, treatment duration, cumulative exposure, and indication) and symptom severity were evaluated using univariate and multivariable regression analyses. Results: The median treatment duration was 24 months (IQR: 12.5–36), and the median time from discontinuation to evaluation was 8 months (IQR: 1–17). Erectile function remained stable over time (mean IIEF: 15.2 ± 0.46 at baseline vs. 15.4 ± 0.47 at 6 months). Depressive symptoms decreased from 12.4 ± 0.41 to 9.1 ± 0.41, and anxiety scores from 3.29 ± 0.23 to 2.54 ± 0.20 over the same period, without normalization in most patients. In multivariable analyses, higher cumulative exposure and older age were independently associated with lower IIEF scores and higher PHQ-9 and GAD-7 scores. Conclusions: In this symptomatic cohort, greater cumulative finasteride exposure and older age were associated with more severe sexual and psychological symptoms after treatment discontinuation. These findings highlight the need for prospective studies to better define risk factors and long-term outcomes.